Next 10 |
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024. Webcast and Conference Call and Details Investors may ac...
2024-07-09 15:00:45 ET More on BioMarin Pharmaceutical, Legend Biotech, etc. Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain Legend Biotech's Carvykti Faces Stiff Challeng...
– Based on promising results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease – CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84 th Scientific Sessions, which were held J...
2024-06-05 11:50:05 ET More on Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals: Hoping Something Sticks Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2024 Earnings Call Transcript Ar...
2024-06-05 05:00:08 ET Andrea Tan from Goldman Sachs issued a price target of $31.00 for ARWR on 2024-06-05 02:24:00. The adjusted price target was set to $31.00. At the time of the announcement, ARWR was trading at $25.29. The overall price target consensus is at $60.00...
2024-06-03 12:24:00 ET More on Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals: Hoping Something Sticks Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point Arrowhead Pharmaceuticals secures $50M milestone from Royalty Pharma Arrow...
- Plozasiran achieved statistically significant median reductions in triglycerides up to 80% and mean reductions in APOC3 up to 94% at month 10 - Plozasiran achieved a statistically significant reduction in incidence of acute pancreatitis versus placebo - Plozasiran is the company’...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 16 th European Glaucoma Society (EGS) Congress – June 1-4, 2024 Title: Development and Characterization of Trabecular Meshwork Targeted RNA...
- Zodasiran significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins across all dose levels at Week 24 - Data presented at European Atherosclerosis Society 92 nd Congress and simultaneously published in the New England Journal of Medicine Arrowhead Pharma...
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
Arrowhead Pharmaceuticals Inc. Website:
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024. Webcast and Conference Call and Details Investors may ac...
– Based on promising results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease – CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84 th Scientific Sessions, which were held J...